Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder

George I. Papakostas, Timothy Petersen, John W. Denninger, Heidi D. Montoya, Andrew A. Nierenberg, Jonathan E. Alpert, Maurizio Fava

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Treatment-related adverse events (TRAEs), particularly those that occur early on, may increase the likelihood for premature discontinuation of antidepressants. The purpose of this study was to examine the relationship between TRAEs and outcome in depressed outpatients enrolled in an 8-week, 20 mg, open trial of fluoxetine. A total of 384 patients (54.7% women, mean age 39.9 ± 10.5 years) were enrolled in the trial. Study visits occurred at baseline and every other week. Somatic complaints were assessed during each study visit. Somatic complaints that, in the opinion of the evaluating physician, were probably related or related to treatment with fluoxetine were entered in the analysis as TRAEs. We then tested whether 1) developing at least one TRAE, 2) developing at least one moderate or severe TRAE, 3) the number of TRAEs reported during the entire trial, or 4) the number of TRAEs reported during each 2-week interval predicted whether patients would respond to fluoxetine, or prematurely discontinue treatment. None of the above scores predicted whether patients responded to or prematurely discontinued the trial. These findings failed to reveal any relationship between side effects and treatment outcome for patients with MDD enrolled in an 8-week, 20 mg, fixed dose, open trial of fluoxetine.

Original languageEnglish (US)
Pages (from-to)187-192
Number of pages6
JournalAnnals of Clinical Psychiatry
Volume15
Issue number3-4
DOIs
StatePublished - Sep 2003
Externally publishedYes

Fingerprint

Fluoxetine
Major Depressive Disorder
Clinical Trials
Therapeutics
Antidepressive Agents
Outpatients
Physicians

Keywords

  • Adverse
  • Event
  • Fluoxetine
  • Outcome

ASJC Scopus subject areas

  • Medicine(all)
  • Psychiatry and Mental health

Cite this

Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder. / Papakostas, George I.; Petersen, Timothy; Denninger, John W.; Montoya, Heidi D.; Nierenberg, Andrew A.; Alpert, Jonathan E.; Fava, Maurizio.

In: Annals of Clinical Psychiatry, Vol. 15, No. 3-4, 09.2003, p. 187-192.

Research output: Contribution to journalArticle

Papakostas, George I. ; Petersen, Timothy ; Denninger, John W. ; Montoya, Heidi D. ; Nierenberg, Andrew A. ; Alpert, Jonathan E. ; Fava, Maurizio. / Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder. In: Annals of Clinical Psychiatry. 2003 ; Vol. 15, No. 3-4. pp. 187-192.
@article{e6286d27550f41b199786bc9c5ce16f2,
title = "Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder",
abstract = "Treatment-related adverse events (TRAEs), particularly those that occur early on, may increase the likelihood for premature discontinuation of antidepressants. The purpose of this study was to examine the relationship between TRAEs and outcome in depressed outpatients enrolled in an 8-week, 20 mg, open trial of fluoxetine. A total of 384 patients (54.7{\%} women, mean age 39.9 ± 10.5 years) were enrolled in the trial. Study visits occurred at baseline and every other week. Somatic complaints were assessed during each study visit. Somatic complaints that, in the opinion of the evaluating physician, were probably related or related to treatment with fluoxetine were entered in the analysis as TRAEs. We then tested whether 1) developing at least one TRAE, 2) developing at least one moderate or severe TRAE, 3) the number of TRAEs reported during the entire trial, or 4) the number of TRAEs reported during each 2-week interval predicted whether patients would respond to fluoxetine, or prematurely discontinue treatment. None of the above scores predicted whether patients responded to or prematurely discontinued the trial. These findings failed to reveal any relationship between side effects and treatment outcome for patients with MDD enrolled in an 8-week, 20 mg, fixed dose, open trial of fluoxetine.",
keywords = "Adverse, Event, Fluoxetine, Outcome",
author = "Papakostas, {George I.} and Timothy Petersen and Denninger, {John W.} and Montoya, {Heidi D.} and Nierenberg, {Andrew A.} and Alpert, {Jonathan E.} and Maurizio Fava",
year = "2003",
month = "9",
doi = "10.1023/B:ACLI.0000008172.20590.22",
language = "English (US)",
volume = "15",
pages = "187--192",
journal = "Annals of Clinical Psychiatry",
issn = "1040-1237",
publisher = "Dowden Health Media,Inc",
number = "3-4",

}

TY - JOUR

T1 - Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Denninger, John W.

AU - Montoya, Heidi D.

AU - Nierenberg, Andrew A.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

PY - 2003/9

Y1 - 2003/9

N2 - Treatment-related adverse events (TRAEs), particularly those that occur early on, may increase the likelihood for premature discontinuation of antidepressants. The purpose of this study was to examine the relationship between TRAEs and outcome in depressed outpatients enrolled in an 8-week, 20 mg, open trial of fluoxetine. A total of 384 patients (54.7% women, mean age 39.9 ± 10.5 years) were enrolled in the trial. Study visits occurred at baseline and every other week. Somatic complaints were assessed during each study visit. Somatic complaints that, in the opinion of the evaluating physician, were probably related or related to treatment with fluoxetine were entered in the analysis as TRAEs. We then tested whether 1) developing at least one TRAE, 2) developing at least one moderate or severe TRAE, 3) the number of TRAEs reported during the entire trial, or 4) the number of TRAEs reported during each 2-week interval predicted whether patients would respond to fluoxetine, or prematurely discontinue treatment. None of the above scores predicted whether patients responded to or prematurely discontinued the trial. These findings failed to reveal any relationship between side effects and treatment outcome for patients with MDD enrolled in an 8-week, 20 mg, fixed dose, open trial of fluoxetine.

AB - Treatment-related adverse events (TRAEs), particularly those that occur early on, may increase the likelihood for premature discontinuation of antidepressants. The purpose of this study was to examine the relationship between TRAEs and outcome in depressed outpatients enrolled in an 8-week, 20 mg, open trial of fluoxetine. A total of 384 patients (54.7% women, mean age 39.9 ± 10.5 years) were enrolled in the trial. Study visits occurred at baseline and every other week. Somatic complaints were assessed during each study visit. Somatic complaints that, in the opinion of the evaluating physician, were probably related or related to treatment with fluoxetine were entered in the analysis as TRAEs. We then tested whether 1) developing at least one TRAE, 2) developing at least one moderate or severe TRAE, 3) the number of TRAEs reported during the entire trial, or 4) the number of TRAEs reported during each 2-week interval predicted whether patients would respond to fluoxetine, or prematurely discontinue treatment. None of the above scores predicted whether patients responded to or prematurely discontinued the trial. These findings failed to reveal any relationship between side effects and treatment outcome for patients with MDD enrolled in an 8-week, 20 mg, fixed dose, open trial of fluoxetine.

KW - Adverse

KW - Event

KW - Fluoxetine

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=0842284007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842284007&partnerID=8YFLogxK

U2 - 10.1023/B:ACLI.0000008172.20590.22

DO - 10.1023/B:ACLI.0000008172.20590.22

M3 - Article

VL - 15

SP - 187

EP - 192

JO - Annals of Clinical Psychiatry

JF - Annals of Clinical Psychiatry

SN - 1040-1237

IS - 3-4

ER -